Back to Search Start Over

Benzodiazepine withdrawal in older people: what is the prevalence, what are the signs, and which patients?

Authors :
Morgane Rousselet
Edouard-Jules Laforgue
Marie Grall-Bronnec
Caroline Victorri-Vigneau
Fanny Feuillet
Morgane Péré
Pascale Jolliet
Alexandra Jobert
MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE)
Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques
Université de Nantes (UN)-Université de Nantes (UN)
Centre hospitalier universitaire de Nantes (CHU Nantes)
Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques
Source :
European Journal of Clinical Pharmacology, European Journal of Clinical Pharmacology, Springer Verlag, 2021, 77 (2), pp.171-177. ⟨10.1007/s00228-020-03007-7⟩
Publication Year :
2021
Publisher :
HAL CCSD, 2021.

Abstract

Benzodiazepines (BZDs) and related drugs (Z-drugs) are mainly taken chronically, and older people are much more likely to take them on a chronic basis despite recommendations. Withdrawal symptoms could be an obstacle to stopping BZD/Z-drug administration. The main objective of this study is to estimate the prevalence of withdrawal symptoms in patients aged 65 years and older who have experience a stop of BZD/Z-drug. The secondary objectives are to describe the withdrawal symptoms and identify factors associated. This ancillary study was based on a national observational study in patients with chronic BZD/Z-drug consumption. Patients who made at least one BZD/Z-drug stop experience were selected. Withdrawal symptoms are described, and a logistic regression was carried out to identify the variables most associated with withdrawal symptoms. In total, 697 patients were selected: 78% experienced at least one withdrawal symptom after a stop administering BZDs or Z-drugs; most of the withdrawal symptoms were psychological disorders. Our study identifies a specific population experiencing withdrawal symptoms and who cannot stop administering BZD/Z-drug. We assume that withdrawal symptoms in patients with chronic use play an essential role in the nonstop use of BZD/Z-drugs.

Details

Language :
English
ISSN :
00316970 and 14321041
Database :
OpenAIRE
Journal :
European Journal of Clinical Pharmacology, European Journal of Clinical Pharmacology, Springer Verlag, 2021, 77 (2), pp.171-177. ⟨10.1007/s00228-020-03007-7⟩
Accession number :
edsair.doi.dedup.....c36d577249b89bfbd91500018c8f0949
Full Text :
https://doi.org/10.1007/s00228-020-03007-7⟩